Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Operating Leases (2018 - 2025)

Historic Operating Leases for Evogene (EVGN) over the last 8 years, with Q3 2025 value amounting to $1.8 million.

  • Evogene's Operating Leases rose 34244.6% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 34244.6%. This contributed to the annual value of $1.9 million for FY2024, which is 6818.98% up from last year.
  • Latest data reveals that Evogene reported Operating Leases of $1.8 million as of Q3 2025, which was up 34244.6% from $2.0 million recorded in Q2 2025.
  • Evogene's 5-year Operating Leases high stood at $2.7 million for Q4 2021, and its period low was $417000.0 during Q3 2024.
  • In the last 5 years, Evogene's Operating Leases had a median value of $1.5 million in 2022 and averaged $1.4 million.
  • As far as peak fluctuations go, Evogene's Operating Leases tumbled by 5117.1% in 2024, and later skyrocketed by 34244.6% in 2025.
  • Quarter analysis of 5 years shows Evogene's Operating Leases stood at $2.7 million in 2021, then plummeted by 31.96% to $1.8 million in 2022, then crashed by 37.33% to $1.1 million in 2023, then skyrocketed by 68.19% to $1.9 million in 2024, then decreased by 3.61% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.0 million for Q2 2025, and $1.9 million during Q1 2025.